Given the significant impact of predicted IL-1RAP expression across all CHIP-associated CAD risks, whether IL-1RAP represents a more effective therapeutic target than individual inflammasomes or their downstream effectors warrants further study. Here, STUB1 is linked to coronary artery disorder.